Amid a global buildout, Cytiva acquires a provider of viral vector manufacturing technologies

12 Oct 2022
endpts.com
Cell Therapy
The life science manufacturer Cytiva has been growing its footprint across the globe this year, but its latest move will see it boost its attention toward the technology for making cell therapies. Cytiva has acquired CEVEC Pharmaceuticals, a Cologne, Germany-based company centered on cell line development and tech for the manufacturing of viral vectors. In an interview with Endpoints News, Cytiva’s president for genomic medicine Emmanuel Abate said that the company has been working with CEVEC for several years and has been watching its technology develop. And while Cytiva has been working to make cell therapies, Abate believes that there can be more improvement on the biology side and the cell lines: While the financial details of the deal were not disclosed to Endpoints, the deal will see CEVEC’s 46 employees brought under Cytiva’s umbrella, with eventual plans to add more, as well as give Cytiva’s customers access to CEVEC’s technology. According to CEVEC’s CEO Nicole Faust, the company has been in the market for a larger partner and believes that its cell line technology will fit seamlessly into Cytiva’s manufacturing. CEVEC is currently working with Cytiva to upscale the technology to work on an industrial scale. Abate said that the company is preparing to boost its AAV production capabilities as with the growth of viral vector trials, there will be a greater need for AAV manufacturing, and Cytiva is bullish about its future. “Of course, it takes time,” Abate said. “I think it is a space where designing a cell line that takes time and seeing it evolve and grow with the trial takes time. We have a long horizon here talking about you know, five to 10 to 15 years, but during that period, we clearly expect the market to continue to grow and CEVEC technology to make good headways.” Cytiva itself has expanded briskly this year as the company acquired a facility in Muskegon, MI with plans to transform the site into a 168,000 square-foot biomanufacturing center. Cytiva also opened an 80,000 square-foot site in Switzerland to produce single-use kits for Sepax and Sefia cell processing systems, and consumables for Xuri cell expansion systems. It also opened a new 118,400 square-foot site in Cardiff to manufacture single-use bioprocessing tech.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.